InnovaDerma PLC
("InnovaDerma" or the "Company")
Director/PDMR shareholding
InnovaDerma (LSE: IDP), a UK developer of beauty, personal care and life sciences products, announces it was notified yesterday that, Mark Ward, Non-executive Director has purchased 171,242 Ordinary shares of €0.10 each in the Company at an average price of 40.7 pence per Ordinary Share.
Following the purchase, Mark Ward now holds a total of 2,345,919 Ordinary Shares representing approximately 13.49% of the issued share capital of the Company. In addition, Mark Ward has agreed to subscribe for 1,428,571 new ordinary shares pursuant to the conditional placing as announced on 20 January 2021.
In addition, InnovaDerma was notified yesterday that, Andrew Dunderdale, Group Finance Director has purchased 24,937 Ordinary shares of €0.10 each in the Company at a price of 40.1 pence per Ordinary Share. Following the Purchase, Andrew Dunderdale now holds Ordinary Shares representing approximately 0.14% of the issued share capital of the Company.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
Further enquiries
| InnovaDerma Blake Hughes
|
c/o TB Cardew
|
| finnCap Ltd Geoff Nash/Kate Bannatyne Alice Lane - Corporate Broking |
+44 (0)207 220 0500 www.finncap.com |
| TB Cardew Shan Shan Willenbrock/ Olivia Rosser |
+ 44 (0)7775 848537 + 44 (0)20 7930 0777
|
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Mark Ward |
| 2. | Reason for the Notification
| |
| a) | Position/status | Non-executive Director |
| b) | Initial notification/Amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |
| a) | Name | InnovaDerma PLC
|
| b) | LEI | 213800WRAP6W8VDL6B38
|
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |
| a) | Description of the Financial instrument, type of instrument | €0.10 each ("Ordinary Shares") |
| Identification code | IDP GB00BT9PTW34
| |
| b) | Nature of the transaction | Purchase of Ordinary Shares
|
| c) | Price(s) and volume(s) | Volume - 2,345,919 Ordinary Shares Average Price - 40.7 pence per Ordinary Share
|
| d) | Aggregated information: Aggregated volume Price |
See 4c) above
|
| e) | Date of the transaction | 15 April 2021
|
| f) | Place of the transaction | London Stock Exchange, Main Market
|
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Andrew Dunderdale |
| 2. | Reason for the Notification
| |
| a) | Position/status | Group Finance Director |
| b) | Initial notification/Amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |
| a) | Name | InnovaDerma PLC
|
| b) | LEI | 213800WRAP6W8VDL6B38
|
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |
| a) | Description of the Financial instrument, type of instrument | €0.10 each ("Ordinary Shares") |
| Identification code | IDP GB00BT9PTW34
| |
| b) | Nature of the transaction | Purchase of Ordinary Shares
|
| c) | Price(s) and volume(s) | Volume - 24,937 ordinary Shares Average Price - 40.1 pence per Ordinary Share
|
| d) | Aggregated information: Aggregated volume Price |
See 4c) above
|
| e) | Date of the transaction | 15 April 2021
|
| f) | Place of the transaction | London Stock Exchange, Main Market
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
